Novartis seeks to collaborate with Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs) in the interest of patients. As an industry we make payments or ‘transfers of value’ to Healthcare Professionals and Organizations to compensate them for the time spent working with us.
In line with the European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Code and its local transpositions, we are disclosing payments and other transfers of value. We also encourage HCPs to consent to individual disclosure when not mandated by local laws or regulations.
Bringing greater transparency to this already well-regulated relationship builds understanding of this collaboration and addresses public concerns about interactions between the medical community and the pharmaceutical industry.
We believe that openly communicating payments and transfers of value related to these interactions helps foster trust with patients, HCPs, government officials and the public and supports our commitment to high ethical business standards.